HopeStage
Back to all studies
Active Not RecruitingNCT06809595

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Researchers are comparing DT120, placebo and a simulated comparison procedure to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.

Medication studyAges 18–74Multiple countries
The study in practice

Understand this study

What is this study about?

Researchers are comparing DT120, placebo and a simulated comparison procedure to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.

Who could participate?

This study is for people with anxiety. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.

Listed locations
Little Rock and 35 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 29, 2025
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
245
Sponsor
Definium Therapeutics US, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, United Kingdom, ...
Age range
From 18 Years to 74 Years
Official registry ID
NCT06809595
Official title
Show the full official title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama

Recruitment & locations

Not recruiting

Little Rock, United States · Los Angeles, United States · Bradenton, United States

26 more locations
  • Orlando, United States
  • Atlanta, United States
  • Towson, United States
  • Boston, United States
  • Princeton, United States
  • Cincinnati, United States
  • North Canton, United States
  • Austin, United States
  • Everett, United States
  • Pilsen, Czechia
  • Prague, Czechia
  • Douai, France
  • Marseille, France
  • Paris, France
  • Sotteville-lès-Rouen, France
  • Berlin, Germany
  • Mannheim, Germany
  • Tübingen, Germany
  • Gdansk, Poland
  • Lodz, Poland
  • Glasgow, United Kingdom
  • Gosforth, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Sheffield, United Kingdom
  • Czechia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing DT120, placebo and a simulated comparison procedure to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.

Who is behind this study?

The study sponsor is Definium Therapeutics US, Inc.

Does this study involve medication?

Yes. The study involves medication, including DT120.

Who can participate?

This study is for people with anxiety. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies